3.30Open3.30Pre Close0 Volume12 Open Interest12.50Strike Price0.00Turnover184.63%IV10.68%PremiumMay 16, 2025Expiry Date2.20Intrinsic Value100Multiplier15DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type-0.6226Delta0.0968Gamma3.40Leverage Ratio-0.0475Theta-0.0036Rho-2.12Eff Leverage0.0081Vega
TYRA BIOSCIENCES, INC. Stock Discussion
Tyra Bio Achieves 54.5% Response Rate in Cancer Trial, Secures 3-Year Runway
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$